Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma

NCT05449483 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
Unresectable

Interventions

DRUG: tislelizumab+ Paclitaxel + Cisplatin

Sponsor

Tianjin Medical University Cancer Institute and Hospital